Alembic Pharma Secures Approval to Manufacture Generic Psoriasis Drug

Alembic Pharmaceuticals announced that it has received approval from the US Food & Drug Administration (USFDA) to market a generic version of Betamethasone Valerate Foam, a medication used to treat moderate-to-severe psoriasis of the scalp.

The final approval is for Alembic's abbreviated new drug application (ANDA) for Betamethasone Valerate Foam, which is therapeutically equivalent to the reference drug Luxiq Foam (0.12 percent) from Norvium Bioscience, LLC. This topical corticosteroid is used to relieve inflammatory and pruritic symptoms of corticosteroid-responsive dermatoses of the scalp.

Following the announcement, Alembic Pharmaceuticals' shares closed 0.97 percent lower at Rs 1,089.90 on the Bombay Stock Exchange (BSE).

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in the macrolides segment of anti-infective drugs in India. They strive to progress the generic pharmaceutical sector through a focus on technology and innovation.

The company has its headquarters and corporate office situated in Vadodara, Gujarat, India, while its manufacturing facilities are located at Panelav, Karakhadi in Gujarat and Sikkim, India. The Panelav facility manufactures active pharmaceutical ingredients (APIs) and formulations, while the Sikkim facility produces formulations for both Indian and non-regulated international markets.